The Hindu | Op-ed | May 30, 2026
With WHO’s declaration of the Bundibugyo Ebola outbreak in DRC + Uganda as a PHEIC (May 17, 2026; Emergency Committee met May 19; India advisory May 21) and 746+ suspected cases (~85 confirmed, including 2 in Uganda) as of mid-May, the editorial argues India’s public-health system must scale up surveillance, point-of-entry screening, and lab capacity without triggering panic — drawing lessons from COVID-19 about what works (rapid testing, transparent communication) and what doesn’t (lockdown overreach, healthcare disruption).
The Argument in One Line
The right response to a PHEIC is calibrated proportionality — neither complacency (which lets pathogens establish) nor panic (which collapses routine healthcare and trust). India has the institutional capacity built post-COVID; what it needs now is disciplined deployment, not headline-grabbing measures.
Why “Not Alarmed” Matters
Past pandemic responses (Ebola West Africa 2014-16, Mpox 2022, COVID-19 2020-23) show two failure modes:
| Failure mode | Consequence |
|---|---|
| Under-response | Pathogen establishment; delayed detection; export to other countries |
| Over-response | Healthcare disruption (collateral mortality from missed routine care); economic harm; loss of public trust; vaccine/testing hesitancy in future emergencies |
The West Africa Ebola epidemic (2014-16) demonstrated the collateral cost of disrupted health systems — excess mortality from missed maternal care, malaria treatment, immunisation, TB control was estimated higher than direct Ebola deaths in Liberia and Sierra Leone.
India’s Risk Profile
| Risk vector | Detail |
|---|---|
| Air connectivity to East Africa | Via Gulf hubs (Dubai, Doha, Abu Dhabi); ~50+ weekly flights between East Africa and Indian cities |
| Diaspora ties | ~3 million people of Indian origin in East/Southern Africa; family-visit travel pattern |
| Vaccine constraint | No licensed vaccine for Bundibugyo ebolavirus; rVSV-ZEBOV (Ervebo) is specific to Zaire strain; limited cross-protection |
| BSL-4 capacity | Only NIV Pune as civilian BSL-4 (commissioned 2012); DRDO Gwalior has a defence BSL-4 |
| Distributed BSL-3 capacity | NCDC Delhi + regional referral centres; not yet primary-care-level |
What India’s Calibrated Response Looks Like
Tier 1 — Border Surveillance
- Thermal screening at airports for incoming passengers from Africa-via-Gulf transit routes (Bengaluru, Kochi, Mumbai, Delhi, Ahmedabad).
- Self-declaration forms on Africa travel for 21-day windows.
- GPS-traced quarantine for high-risk contacts (modelled on Aarogya Setu architecture but voluntary).
Tier 2 — Lab + Surveillance Capacity
- NIV Pune activated as confirmatory lab for VHF samples.
- Regional BSL-3 capacity expanded — Bengaluru, Kolkata, Hyderabad, Ahmedabad.
- IDSP (Integrated Disease Surveillance Programme) alert protocols for VHF case definitions.
Tier 3 — Healthcare Continuity
- No lockdown unless community transmission detected.
- Routine healthcare continuity protocols — maternal care, immunisation, TB/HIV continuity guaranteed.
- Risk communication via authoritative channels (NCDC, MoHFW, state health departments) — counter misinformation.
Tier 4 — International Coordination
- WHO + Africa CDC engagement.
- Vaccine equity — push Bharat Biotech / Serum Institute / Biological E for vaccine development on Bundibugyo and other non-Zaire strains.
- India-Africa Forum Summit (IAFS-IV) — postponed from May 28-31, 2026; reschedule with health-protocol clauses.
Post-COVID Lessons — Five
- Test, don’t lockdown — diagnostic capacity (PCR, antigen, sequencing) is the highest-yield investment.
- Genome sequencing routine — India’s INSACOG network must remain funded and operational for VHF-relevant pathogens.
- Healthcare worker training + PPE — pre-positioned at high-risk hospitals.
- Transparent communication — daily public-health bulletins; clear case-counts; honest unknowns.
- One Health integration — animal + environmental surveillance under the National One Health Mission (₹2,233 crore, March 2024).
What the Editorial Pushes Back Against
- Travel-ban politics — blanket travel bans on Africa would be diplomatically costly (IAFS-IV postponement is already a cost) and epidemiologically ineffective.
- Vaccine nationalism — India should NOT hoard rVSV-ZEBOV doses (which are limited globally); instead push for production capacity sharing.
- Headline-grabbing surge capacity — building emergency hospitals before need is established is performative; the investment is better placed in routine BSL-3 network + R&D for non-Zaire vaccines.
UPSC Hooks
| Paper | Angle |
|---|---|
| GS2 | WHO architecture; IHR-2005; PHEIC; India-Africa Forum Summit; health diplomacy; vaccine equity |
| GS3 | One Health; pandemic preparedness; BSL-3/4 capacity; lab network; INSACOG; risk communication |
| GS4 | Ethics of pandemic response — proportionality, transparency, equity |
| Mains | “India’s post-COVID pandemic preparedness must move beyond reactive surveillance to integrated One Health and proportionate response. Discuss with reference to the current Ebola PHEIC.” |
| Prelims | PHEIC under IHR-2005 (in force June 15, 2007); current PHEICs (Polio 2014–, Mpox clade Ib 2024–, Ebola Bundibugyo 2026–); rVSV-ZEBOV (Ervebo, Zaire-only); NIV Pune (BSL-4, 2012); NCDC; IDSP; INSACOG; National One Health Mission (₹2,233 cr, March 2024); WHO Pandemic Agreement (78th WHA, May 20, 2025); IAFS-IV postponement |
Cross-Links
- WHO Ebola PHEIC declaration (May 17, 2026; Emergency Committee May 19; India advisory May 21)
- 6 Ebolavirus species (Zaire, Sudan, Bundibugyo, Tai Forest, Reston, Bombali)
- India-Africa Forum Summit IV (postponed)
- National One Health Mission (March 2024)
- WHO Pandemic Agreement (May 20, 2025)
- Daily article: who-ebola-pheic-india-advisory-2026
Source: On Ebola, India Must Stay Alert — Not Alarmed — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
